Results 191 to 200 of about 1,205,800 (294)

Health Research Funders and Justice: Obligations to Coordinate and Counterbalance

open access: yesBioethics, EarlyView.
ABSTRACT Government health research funders are frequently criticized on the grounds that their distribution of resources fails to reflect a population's disease burden. These critiques do not take into account what other research funders are doing. In this paper, I argue that this is a mistake.
Joseph Millum
wiley   +1 more source

The association between inborn errors of immunity and Hodgkin lymphoma—A register‐based case–control study in Sweden

open access: yesBritish Journal of Haematology, EarlyView.
Summary Immune dysfunction is implicated in the aetiology of Hodgkin lymphoma (HL), but the association between inborn errors of immunity (IEI) and HL remains poorly understood. We conducted a retrospective, register‐based case–control study in Sweden over five decades to investigate the relationship between IEI and HL. Individuals diagnosed with HL in
Agnes Winsa   +7 more
wiley   +1 more source

Economic Burden of Overweight and Obesity in Sweden: Current Estimates and Future Projections

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Overweight and obesity are major public health challenges and well‐established risk factors for cardiovascular disease, cancer and premature mortality. We estimated the economic burden of overweight and obesity in Sweden in 2023 and projected the future economic burden in 2040 under alternative scenarios of increasing prevalence ...
Adam Fridhammar   +5 more
wiley   +1 more source

Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objective This study aimed to evaluate the feasibility and safety of venetoclax as a cytoreductive strategy during induction therapy in newly diagnosed acute promyelocytic leukemia (APL), and to provide an exploratory description of its early efficacy.
Yu Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy